Drug Database
Back to search

Netherlands· NL-4bf66dcaa9d8

Columvi 2,5 mg concentraat voor oplossing voor infusie

A other monoclonal antibodies and antibody drug conjugates product containing glofitamab, registered in Netherlands by Roche Registration GmbH. The same ATC class is registered in 5 of our 19 countries.

ATC L01FX

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedColumvi 2,5 mg concentraat voor oplos…ATCL01FXREGISTER NO.NL-4bf66dcaa9d8PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about glofitamabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Glofitamab is registered in 5 of 19 countries.

Countries holding a registration under ATC L01FX (other monoclonal antibodies and antibody drug conjugates), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 4 of them publish a price we can compare per daily dose
Search glofitamab products by name

Glofitamab · ATC L01FX

5 / 19 countries

  • Finlandprice
  • Icelandprice
  • Netherlands
  • Polandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
GLOFITAMAB
Manufacturer
Roche Registration GmbH
Country
Netherlands (NL)
ATC code
L01FX
ATC class
Other monoclonal antibodies and antibody drug conjugates
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/23/1742

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Glofitamab in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All glofitamab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Columvi
  • Liechtenstein · Columvi
  • Norway · Columvi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/aa1b8143-bfd5-47c8-95ff-0b944a5c71c4
GET /v1/drugs/aa1b8143-bfd5-47c8-95ff-0b944a5c71c4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/columvi-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Other monoclonal antibodies and antibody drug conjugates",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp129852",
  "excipients": [
    "HISTIDINE, (L-)",
    "HISTIDINEMONOHYDROCHLORIDE 1-WATER (L-)",
    "METHIONINE, (L-)",
    "POLYSORBAAT 20 (E 432)",
    "SACCHAROSE",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "GLOFITAMAB"
  ],
  "leaflet_url": null,
  "authorised_at": "2023/07/07",
  "procedure_number": "EMEA/H/C/005751",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/23/1742",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about glofitamab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console